DEFA14A: BlackRock Health Sciences Term Trust Faces Proxy Battle Ahead of Annual Meeting

BlackRock urges shareholders to vote in favor of its board nominees and against a proposal by Saba Capital to terminate BlackRock as investment manager, highlighting the fund's performance and discount management program.

Summary

• BlackRock is urging shareholders of the BlackRock Health Sciences Term Trust (BMEZ) to vote in favor of its board nominees and against a proposal by Saba Capital to terminate BlackRock as the investment manager.
• The annual meeting is scheduled for June 25th.
• BlackRock highlights its performance, stating it has delivered total shareholder returns of 8.8% since 2023, more than doubling peers' returns.
• They also claim to have improved the discount by 5.2%, generating $130 million in value for shareholders.
• A discount management program is in place, providing shareholders with an additional 9.8% of annual liquidity at NAV.
• BlackRock argues that Saba's nominees are underqualified and that Saba's true aim is a quick profit at the expense of the fund and its shareholders.
• They also state that Saba has never launched a closed-end fund, only taken them over, and pursued riskier strategies that may no longer serve the investment goals of shareholders.
• Leading independent proxy advisors, ISS and Glass Lewis, recommend voting against terminating BlackRock as investment manager and for all Board nominees.
• Shareholders are instructed to vote using the WHITE proxy card and disregard any gold proxy cards from Saba.

Sentiment

Score: 7

Explanation: The document presents a confident and assertive tone, highlighting positive performance metrics and defending against an activist investor. However, the presence of a proxy battle introduces uncertainty.

Positives

• BlackRock highlights an 8.8% total shareholder return since 2023, exceeding peer performance.
• The fund's discount has improved by 5.2%, resulting in $130 million in value for shareholders.
• The discount management program provides 9.8% annual liquidity at NAV.
• Independent proxy advisors ISS and Glass Lewis support BlackRock's position.

Negatives

• Saba Capital is attempting to replace BlackRock as the investment manager.
• BlackRock claims Saba's nominees are underqualified and focused on short-term profits.
• Saba is accused of pursuing riskier strategies in other funds that may not align with current shareholder goals.

Risks

• The potential termination of BlackRock as the investment manager could disrupt the fund's strategy.
• Saba's proposed strategies may introduce increased risk and fees.
• The outcome of the proxy vote is uncertain and could impact the fund's future direction.

Future Outlook

The fund intends to offer to repurchase 2.5% of its outstanding common shares at a price equal to 98% of NAV following the end of each quarter (June 30, 2024, September 30, 2024, December 31, 2024, and March 31, 2025) if the fund's common shares trade at a discount of more than 7.5% during each of those quarters.

Management Comments

• BlackRock and your Board continue to deliver for you.
• Saba's true aim is a quick profit for themselves at the expense of your Fund and shareholders like you.
• Saba has never launched a closed-end fundjust taken them over.

Industry Context

This proxy battle reflects a broader trend of activist investors targeting closed-end funds to unlock value or influence management decisions. Saba Capital is a known activist investor in the closed-end fund space.

Comparison to Industry Standards

• The document states that BlackRock Health Sciences Term Trust (BMEZ) has delivered total shareholder returns of 8.8% since 2023, more than doubling peers' returns.
• The peer set includes all closed-end funds in the Morningstar Health category (ex-BMEZ).
• Without specific data on the performance of other health sciences closed-end funds, it's difficult to provide a detailed comparison.
• However, the claim of 'more than doubling peers' returns' suggests a significant outperformance relative to the average in that category.

Stakeholder Impact

• Shareholders will be impacted by the outcome of the proxy vote, which will determine the fund's management and investment strategy.
• The fund's performance and discount management program affect shareholder value.
• Employees of BlackRock involved in managing the fund could be affected if Saba's proposal succeeds.

Next Steps

• Shareholders need to vote on the board nominees and the proposal to terminate BlackRock as investment manager by June 24, 2024.
• The annual meeting will be held on June 25th.

Key Dates

Keywords

BlackRock, BMEZ, Saba Capital, Proxy Fight, Shareholder Vote, Investment Manager, Health Sciences Term Trust, Closed-End Fund